Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent o...

Full description

Bibliographic Details
Main Authors:	de Dueñas, Eduardo Martínez, Hernández, Ana Lluch, Zotano, Ángel Guerrero, Carrión, Ramón María Pérez, López-Muñiz, José Ignacio Chacón, Novoa, Silvia Antolín, Rodríguez, Ángela López, Fidalgo, José Alejandro Pérez, Lozano, Jaime Ferrer, Gasión, Octavio Burgués, Carrascal, Eva Carrasco, Capilla, Andrés Hernando, López-Barajas, Isabel Blancas, Mateu, Montserrat Muñoz, de Ceballos Reyna, María Helena López, Ferrando, Amparo Oltra, Jañez, Noelia Martínez, Ballerini, Vicente Carañana, Torres, Antonio Antón, Catalán, Gustavo, Sáenz, José Ángel García, Menjón, Salomón, González-Angulo, Ana María
Format:	Online
Language:	English
Published:	Springer US 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907670/

id	pubmed-3907670
recordtype	oai_dc
spelling	pubmed-39076702014-02-04 Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study de Dueñas, Eduardo Martínez Hernández, Ana Lluch Zotano, Ángel Guerrero Carrión, Ramón María Pérez López-Muñiz, José Ignacio Chacón Novoa, Silvia Antolín Rodríguez, Ángela López Fidalgo, José Alejandro Pérez Lozano, Jaime Ferrer Gasión, Octavio Burgués Carrascal, Eva Carrasco Capilla, Andrés Hernando López-Barajas, Isabel Blancas Mateu, Montserrat Muñoz de Ceballos Reyna, María Helena López Ferrando, Amparo Oltra Jañez, Noelia Martínez Ballerini, Vicente Carañana Torres, Antonio Antón Catalán, Gustavo Sáenz, José Ángel García Menjón, Salomón González-Angulo, Ana María Clinical Trial The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. Overall, 196 patients were included and 184 patients were considered evaluable. Reasons for non-evaluability included the inability to perform biopsy (n = 4) or biopsy results showing normal tissue (n = 3), benign disease (n = 3) or a second neoplasia (n = 2). Conversion rates determined at local level were higher than those determined centrally (HER2: 16 vs. 3 %, ER: 21 vs. 13 %, PR: 35 vs. 28 %, respectively). There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. PR at any site and ER at primary site showed moderate agreement. Oncologists altered their treatment plans in 31 % of patients whose tumor subtype had changed. These results reinforce the recommendation for performing confirmatory biopsies of metastases, not only to avoid misdiagnosis of breast cancer relapse, but also to optimize treatment (clinicaltrials.gov identifier: NCT01377363). Springer US 2014-01-11 2014 /pmc/articles/PMC3907670/ /pubmed/24414130 http://dx.doi.org/10.1007/s10549-013-2825-2 Text en © The Author(s) 2014 Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	de Dueñas, Eduardo Martínez Hernández, Ana Lluch Zotano, Ángel Guerrero Carrión, Ramón María Pérez López-Muñiz, José Ignacio Chacón Novoa, Silvia Antolín Rodríguez, Ángela López Fidalgo, José Alejandro Pérez Lozano, Jaime Ferrer Gasión, Octavio Burgués Carrascal, Eva Carrasco Capilla, Andrés Hernando López-Barajas, Isabel Blancas Mateu, Montserrat Muñoz de Ceballos Reyna, María Helena López Ferrando, Amparo Oltra Jañez, Noelia Martínez Ballerini, Vicente Carañana Torres, Antonio Antón Catalán, Gustavo Sáenz, José Ángel García Menjón, Salomón González-Angulo, Ana María
spellingShingle	de Dueñas, Eduardo Martínez Hernández, Ana Lluch Zotano, Ángel Guerrero Carrión, Ramón María Pérez López-Muñiz, José Ignacio Chacón Novoa, Silvia Antolín Rodríguez, Ángela López Fidalgo, José Alejandro Pérez Lozano, Jaime Ferrer Gasión, Octavio Burgués Carrascal, Eva Carrasco Capilla, Andrés Hernando López-Barajas, Isabel Blancas Mateu, Montserrat Muñoz de Ceballos Reyna, María Helena López Ferrando, Amparo Oltra Jañez, Noelia Martínez Ballerini, Vicente Carañana Torres, Antonio Antón Catalán, Gustavo Sáenz, José Ángel García Menjón, Salomón González-Angulo, Ana María Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
author_facet	de Dueñas, Eduardo Martínez Hernández, Ana Lluch Zotano, Ángel Guerrero Carrión, Ramón María Pérez López-Muñiz, José Ignacio Chacón Novoa, Silvia Antolín Rodríguez, Ángela López Fidalgo, José Alejandro Pérez Lozano, Jaime Ferrer Gasión, Octavio Burgués Carrascal, Eva Carrasco Capilla, Andrés Hernando López-Barajas, Isabel Blancas Mateu, Montserrat Muñoz de Ceballos Reyna, María Helena López Ferrando, Amparo Oltra Jañez, Noelia Martínez Ballerini, Vicente Carañana Torres, Antonio Antón Catalán, Gustavo Sáenz, José Ángel García Menjón, Salomón González-Angulo, Ana María
author_sort	de Dueñas, Eduardo Martínez
title	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
title_short	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
title_full	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
title_fullStr	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
title_full_unstemmed	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
title_sort	prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the geicam 2009-03 converther study
description	The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. Overall, 196 patients were included and 184 patients were considered evaluable. Reasons for non-evaluability included the inability to perform biopsy (n = 4) or biopsy results showing normal tissue (n = 3), benign disease (n = 3) or a second neoplasia (n = 2). Conversion rates determined at local level were higher than those determined centrally (HER2: 16 vs. 3 %, ER: 21 vs. 13 %, PR: 35 vs. 28 %, respectively). There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. PR at any site and ER at primary site showed moderate agreement. Oncologists altered their treatment plans in 31 % of patients whose tumor subtype had changed. These results reinforce the recommendation for performing confirmatory biopsies of metastases, not only to avoid misdiagnosis of breast cancer relapse, but also to optimize treatment (clinicaltrials.gov identifier: NCT01377363).
publisher	Springer US
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907670/
_version_	1612053086939906048

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Similar Items